Protective effect of silymarin against chemical-induced cardiotoxicity

Iranian Journal of Basic Medical Sciences

Volumn 19, Issue 9, 2016, Pages 916-923

  Razavi, Bibi Marjan ^a   Karimi, Gholamreza ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiotoxicity; Metals; Oxidative stress; Silybum marianum; Silymarin

Indexed keywords

ACROLEIN; ANTIOXIDANT; ARSENIC; ASCORBIC ACID; CISPLATIN; COPPER; DEFEROXAMINE; DOXORUBICIN; HYDROGEN PEROXIDE; IRON; ISOPRENALINE; PHENYLEPHRINE; SILIBININ; SILYMARIN; SODIUM FLUORIDE;

CARDIOTOXICITY; CELL VIABILITY; CHEMICALLY INDUCED DISORDER; HEART PROTECTION; HUMAN; IRON OVERLOAD; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; REVIEW; SICKLE CELL ANEMIA; THALASSEMIA; UPREGULATION;

EID: 84992371620     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: 10.22038/ijbms.2016.7590     Document Type: Review

References (60)

1. Negi A, Kumar J, Luqman S, Shanker K, Gupta M, Khanuja S. Recent advances in plant hepatoprotectives: A chemical and biological profile of some important leads. Med Res Rev 2008; 28: 746-772.
2. Luper S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 1998; 3: 410-421.
3. Pepping J. Milk thistle: Silybum marianum,. Am J Health System Pharm 1999; 56: 1195-1197.
4. Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. Silymarin, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 2011; 14: 308-317.
5. Dixit N, Baboota S, Kohli K, Ahmad S, Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol 2007; 39: 172-179.
6. Karimi G, Hassanzadeh M, Mehri S. Protective effects of Silymarin against free radical-induced erythrocyte lysis, J Altern Complementary Med. 2006; 3:8.
7. Nazemian F. Effect of silymarin administration on TNF-α serum concentration in peritoneal dialysis patients. Phytother Res 2010; 24:1654–1657.
8. Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 2009; 42: 229-240.
9. Taghiabadi T, Imenshahidi M, Abnous K, Mosafa F, Sankian M, Karimi G. Protective Effect of Silymarin against acrolein-induced cardiotoxicity in mice. Evid Based Complementary Altern Med 2012; 2012: Article ID 352091.
10. Muthumani M, Milton Prabu S. Silibinin potentially attenuates arsenic-induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. Cardiovasc Toxicol 2014; 14: 83-97.
11. Karimi G, Saradeghi Keisari M. Evaluation of antidepressant effect of ethanolic and aqueous extracts of Silybum marianum L. seed in mice. J Med Plants 2007; 6: 38-43.
12. Morishima C, Shuhart M, Wang CC, Paschal D, Apodaca M, Liu Y. Silymarin inhibits in vitro cell proliferation and cytokine production in hepatitis c virus infection. Gastroenterology 2010; 138: 671-681.
13. Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complementary Altern Med 2005a; 2: 383-386.
14. Karimi G, Fallah Huseini H, Ramezani M, Tahoonian Z. Protective effect of silybum marianum(l.) gaertn. seeds extract and silymarin against cisplatin-induced acute nephrotoxicity in rats. J Med Plants 2005b; 4: 42-45.
15. Chu S, Chiou H, Chen P, Yang S, Hsieh Y. Silybinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog 2004; 40: 143-149.
16. Kanter M, Meral I, Yener Z. Partial regeneration/ proliferation of the beta-cells in the islets of Langerhans by Nigella sativa L. in streptozotocin-induced diabetic rats. J Exp Med 2003; 201: 213-219.
17. Toklu H, Tunali-Akbay T, Erkanli G, Yuksel M, Ercan F, Sener G. Silymarin, the antioxidant component of Silybum marianum, protects against burn-induced oxidative skin injury. Burns 2007; 33: 908-916.
18. Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komp Klas Nat 2007; 14: 70-80
19. Fleming T. PDR for Herbal Medicines. New Jersy Medical Economics Company, 2000; 516-518
20. Kren V, Walterova D. Silybin and silymarin, new effects and applications. Biomed Papers 2005; 149: 29-41.
21. Rao P, Viswanath R. Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. Exp Clin Cardiol 2007; 12: 179-187.
22. Talha J, Priyanka M A A. Hypertension and herbal plants. Int Res J Pharm 2011; 2: 26-30.
23. Sinha M, Manna P, SIL P. Terminalia arjuna protects mouse hearts against sodium fluoride-induced oxidative stress. J Med Food 2008; 11:733-740.
24. Nabavi S, Moghaddam A, Setzer W, Mirzaei M. Effect of silymarin on sodium fluoride-induced toxicity and oxidative stress in rat cardiac tissues. Anais da Academia Brasileira de Ciências 2012; 84: 1121-1126.
25. Murphy C. G. Oudit. Iron-overload cardiomyo-pathy: Pathophysiology, diagnosis, and treatment. J Card Fail 2010; 16: 888-900.
26. Wang Y, Wu M, Al-Rousan R, Liu H, Fannin J, Paturi S. Iron-induced cardiac damage: Role of apoptosis and deferasirox intervention. J Pharmacol Exp Ther 2011; 336: 56-63.
27. Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S. Silybin, a new iron-chelating agent. J Inorg Biochem 2001; 85: 123-129.
28. Gharagozloo M, Khoshdel Z, Amirghofran Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: A comparison with desferrioxamine. Eur J Pharmacol 2008; 589: 1-7.
29. Najafzadeh H, Jalali M, Morovvati H, Taravati F. Comparison of the Prophylactic Effect of Silymarin and Deferoxamine on Iron Overload-Induced Hepatotoxicity in Rat. J Med Toxicol 2010; 6: 22-26.
30. Navidi-Shishaone M, Mohhebi S, Nematbakhsh M, Roozbehani S, Talebi A, Pezeshki Z, Eshraghi-Jazi F, Mazaheri S, Shirdavani S, Gharagozloo M, Alsaadat Moaeidi B. Co-administration of silymarin and deferoxamine against kidney, liver and heart iron deposition in male iron overload rat model. Int J Prev Med 2014; 5: 110-116.
31. Moon K, Guallar E, Navas–Acien A. Arsenic Exposure and Cardiovascular Disease: An Updated Systematic Review. Curr Atheroscler Rep 2012; 14: 542-555.
32. Manna P, Sinha MPS. Arsenic induced oxidative myocardial injury: Protective role of arjunolic acid. Arch Toxicol 2008; 82:137-149.
33. Alamolhodaei NS, Shirani K, Karimi G. Arsenic cardiotoxicity: An overview. Env Toxicol Pharmacol 2015; 40: 1005-1014.
34. Yamauchi H, Aminaka Y, Yoshida K, Sun G, Pi J, Waalkes M. Evaluation of DNA damage in patients with arsenic poisoning: Urinary 8-hydroxydeoxyguanine. Toxicol Appl Pharmacol 2004; 198: 291-296.
35. Dutta M, Ghosh A, Rangari V, Jain G, Khobragade S, Chattopadhyay A, Bhowmick D, Das T, Bandyopadhyay D. Silymarin protects against copper-ascorbate induced injury to goat cardiac mitochondria in vitro: involvement of antioxidant machnism. Int J Pharm Pharm Sci 2014; 6: 422-429.
36. Miltonprabu S, Thangapandiyan S. Epigallocatechin gallate potentially attenuates Fluoride induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. J Trace Elem Med Biol 2015; 29: 321-335.
37. Shashi A, Thapar S. Histopathology of myocardial damage in experimental fluorosis in rabbits. Fluoride 2001; 34: 43-50.
38. Donmez N, Cinar A. Effects of chronic fluorosis on electrocardiogram in sheep. Biol Trace Elem Res 2003; 2:115-122.
39. Nabavi S, Nabavi SF, Eslami S, Moghaddam A. In vivo protective effects of quercetin against sodium fluoride-induced oxidative stress in the hepatic tissue. Food ChemToxicol 2012; 132: 931-935.
40. Ma Y, Niu R, Sun Z, Wang J, Luo G, Zhang J, Wang J. Inflammatory responses induced by fluoride and arsenic at toxic concentration in rabbit aorta. Arch Toxicol 2012; 86: 849-856.
41. Diwan A, Dorn G. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology 2007; 22: 56-64.
42. Molkentin J, Dorn G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001; 63: 391-426.
43. Bernardo B. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010; 128: 191-227.
44. Takimoto E, Kass D. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49: 241-248.
45. Anestopoulos I, Kavoa A, Tentesc I, Kortsarisc A, Panayiotidisd M, Lazoub A, Pappaa A. Silibinin protects H9c2 cardiac cells from oxidative stress and inhibits phenylephrine-induced hypertrophy: potential mechanisms. J Nut Biochem 2013; 24: 586-594.
46. Cieslak D, Lazou A. Regulation of BAD protein by PKA, PKCdelta and phosphatases in adult rat cardiac myocytes subjected to oxidative stress.. Mol Cells 2007; 24: 224-231.
47. Communal C. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 1998; 98: 1329-1334.
48. Zhou B, Wu L, Li L, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Silibinin protects against isoproterenol-induced rat cardiac myocyte injury through mitochondrial pathway after up-regulation of SIRT1. J Pharmacol Sci 2006a; 102: 387-395.
49. Zhou B, Wu L, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Silibinin Protects Rat Cardiac Myocyte from Isoproterenol-Induced DNA Damage Independent on Regulation of Cell Cycle. Biol Pharm Bull 2006b; 29: 1900-1905.
50. Zhou B, Wu L, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Activation of extracellular signal-regulated kinase during silibinin protected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent. Acta Pharmacol Sin 2007; 28: 803-810.
51. Faroon O, Roney N, Taylor J, Ashizawa A, Lumpkin M, Plewak D. Acrolein health effects. Toxicol Ind Health 2008; 24: 447-490.
52. Stevens J, Maier C. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol Nut Food Res 2008; 52: 7-25.
53. Raschi E, Vasina V, Ursino M. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010; 125: 196-218.
54. Ado R, de Keulenaer G, Leite-Moreira A, Brs-Silva C. Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. Rev Port Cardiol. 2013;32:395-409.
55. Blum R, Carter S. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80: 249-259.
56. El-Shitany N, El-Haggar S, El-desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food ChemToxicol 2008; 46: 2422–2428.
57. Chlopcikova S, Psotová P, Miketová P, Šimánek V. Chemoprotective Effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. part I. Silymarin and its flavonolignans. Phytother Res 2004; 18: 107-110.
58. Cecen E, Dost T, Culhaci N, Karul A, Ergur B, Birincioglu M. Protective effects of silymarin against doxorubicin-induced toxicity. Asian Pacific J Cancer Prev 2011; 12: 2697-2704.
59. Psotová J, Chlopčíková S, Grambal F, Šimánek V, Ulrichová J. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res 2002; 16: S63-S67.
60. El-Awady E, Moustafa Y, Abo-Elmatty D, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650: 335-341.